Table 5.
No. of first infections | No. of patients at risk | Fully adjusted HR (95% CI) | ||||
---|---|---|---|---|---|---|
MTX | Taking ETN | MTX | Taking ETN | MTX | Taking ETN | |
MSIs | ||||||
Time points | ||||||
0–6 months | 9 | 48 | 260 | 852 | Reference | 2.00 (0.89–4.46) |
6–12 months | 6 | 26 | 211 | 716 | Reference | 1.09 (0.43–2.78) |
12–18 months | 4 | 18 | 160 | 564 | Reference | 2.68 (0.58–12.42) |
18–24 months | 1 | 16 | 138 | 470 | Reference | 4.13 (0.51–33.50) |
SIs | ||||||
Time points | ||||||
0–6 months | 5 | 24 | 260 | 852 | Reference | 0.93 (0.32–2.73) |
6–12 months | 5 | 12 | 215 | 738 | Reference | 0.36 (0.11–1.231) |
12–18 months | 2 | 9 | 166 | 595 | Reference | 1.61 (0.19–13.86) |
18–24 months | 1 | 9 | 143 | 506 | Reference | 1.37 (0.15–12.19) |
Hazard ratios (HRs) were fully adjusted using propensity deciles (including age, sex, Childhood Health Assessment Questionnaire score, Juvenile Arthritis Disease Activity Score in 71 joints, concurrent steroid use, and International League of Associations for Rheumatology category). ETN = etanercept; MTX = methotrexate; 95% CI = 95% confidence interval.